Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

The pharmacogenomics sector is rapidly evolving as advancements in genetic research and personalized medicine transform healthcare approaches. With a growing focus on tailoring treatments to individual genetic profiles, this market is set to experience substantial growth driven by technological innovations and increasing demand for precision therapies. Below is a detailed overview of the market size, key drivers, segmentation, innovation trends, major players, and regional insights shaping the future of pharmacogenomics.

Pharmacogenomics Market Size and Growth Projections

The pharmacogenomics market has witnessed significant expansion in recent years. It is projected to increase from $9.84 billion in 2025 to $10.85 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. This historic growth stems from a surge in genomic research activities, advancements in targeted therapy development, a rising prevalence of chronic diseases, enhancements in sequencing technologies, and wider access to genetic testing services. Looking ahead, the market is expected to reach $15.98 billion by 2030, maintaining a CAGR of 10.2%. Factors propelling this forecasted growth include increased investments in precision medicine, broader adoption of AI-driven genomic analyses, expansion of pharmacogenomics applications in oncology and cardiology, a focus on personalized drug development, and continuous progress in bioinformatics platforms. Emerging trends during this period involve greater use of personalized medicine, genetic testing for drug selection, integration of pharmacogenomic data into clinical workflows, growth in companion diagnostics, and heightened emphasis on precision therapeutics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

Primary Factors Boosting Demand in the Pharmacogenomics Market

One of the main drivers of the pharmacogenomics market is the rising incidence of chronic diseases worldwide. Chronic conditions often persist throughout a patient’s life and are becoming increasingly common due to longer life expectancies and lifestyle factors like sedentary behavior, unhealthy diets, and tobacco use. Pharmacogenomics provides a way to tailor treatments based on an individual’s genetic makeup, which influences their response to medications. For instance, as per the International Diabetes Federation in 2025, approximately 589 million adults aged 20-79 had diabetes in 2024, with projections reaching 853 million by 2050. Notably, over 80% of these individuals live in low- and middle-income countries. This growing burden of chronic illnesses is a key factor driving the pharmacogenomics market forward.

Expanding Role of Genetic Testing and Precision Medicine in Market Growth

In addition to chronic diseases, the increasing availability and adoption of genetic testing and precision medicine programs are fueling market expansion. These approaches enable more effective and safer treatments by considering genetic differences among patients. As a result, healthcare providers are integrating pharmacogenomic data more frequently into clinical decision-making processes, further accelerating demand for related technologies and services.

Access The Complete Pharmacogenomics Market Report:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

Detailed Market Segmentation of Pharmacogenomics

This market is categorized across several important dimensions:

1) By Technology: Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Gel Electrophoresis, Mass Spectrometry, Microarray, and Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, and Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, and Other End Users

Further breakdowns include:

– NGS subdivided into Whole Genome Sequencing, Targeted Sequencing, and Exome Sequencing

– PCR categories such as Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), and Digital PCR

– Gel Electrophoresis split into Agarose, Polyacrylamide, and Capillary methods

– Mass Spectrometry types including LC-MS/MS, MALDI-TOF MS, and High-Resolution MS

– Microarray variants like SNP Microarrays, Expression Microarrays, and Comparative Genomic Hybridization Arrays

– Other Technologies encompassing Sanger Sequencing, CRISPR-based tools, and Bioinformatics platforms

Key Innovations in Pharmacogenomics Shaping the Industry

Leading players in pharmacogenomics are increasingly turning to artificial intelligence (AI) to enhance drug safety and personalize treatment plans. AI-powered pharmacogenetic engines analyze genetic profiles to predict drug responses and manage drug-drug interactions more effectively, reducing adverse effects and improving outcomes. For example, in December 2024, US-based company PGxAI introduced its Sirius model—a sophisticated AI-driven pharmacogenetics platform. Covering 730 medications and 40 key pharmacogenes, Sirius supports hospitals, diagnostic labs, and clinical research organizations by optimizing drug choice, dosage, and interaction management at an individual genetic level. This initiative represents a significant leap beyond traditional pharmacogenomics solutions.

Major Competitors Leading the Pharmacogenomics Market

The market features several prominent companies driving innovation and growth, including: Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, and Genomika Diagnósticos.

Regional Outlook and Areas of Rapid Market Growth

In 2025, North America held the largest share of the pharmacogenomics market, driven by advanced healthcare infrastructure and ongoing research investments. However, the Asia-Pacific region is projected to be the fastest-growing market in the coming years. The comprehensive market analysis includes regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, reflecting the global reach and expanding demand for pharmacogenomics solutions.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model